オレキシン拮抗薬市場レポート：動向、予測、競合分析 (2031年まで)

世界のオレキシン拮抗薬市場の将来は、病院・診療所市場と小売薬局市場に機会がありそうです。世界のオレキシン拮抗薬市場は、2025年から2031年にかけてCAGR 7.2％で成長すると予想されます。この市場の主な促進要因は、睡眠障害の有病率の増加、効果的な不眠症治療に対する需要の高まり、オレキシン拮抗薬に対する意識の高まりです。

• Lucintel社の予測では、種類別では、デュアルオレキシン受容体拮抗薬が予測期間中に高い成長を遂げる見込みです。
• 用途別では、病院・診療所がより高い成長が見込まれます。
• 地域別では、北米が予測期間中に最も高い成長が見込まれます。

オレキシン拮抗薬市場の新たな動向

オレキシン拮抗薬市場は、睡眠生理学に関する知識の向上、患者の要求の変化、革新的な医薬品開発といったいくつかの大きな動向に後押しされています。これらの動向は、製品開発、臨床アプローチ、睡眠障害治療への全体的なアプローチに影響を与え、より特異的で患者志向の治療へと変化しています。

• 慢性不眠症の治療：オレキシン拮抗薬を慢性不眠症の治療薬として位置づける傾向は明確であり、単に鎮静するのではなく、覚醒亢進の根本的なメカニズムを治療する可能性を強調しています。この点を強調することで、旧来の催眠薬とは一線を画し、より自然な睡眠と日中の機能改善による長期管理が期待されます。
• 不眠症以外の適応の探求：不眠症に加え、研究者たちは、不安、うつ病、薬物乱用など、オレキシン系が関与するその他の疾患に対するオレキシン拮抗薬の調査を積極的に行っています。この開発は、他の精神疾患や神経疾患への市場開拓が期待され、新たな治療の可能性を開くものです。
• 選択的オレキシン拮抗薬の開発：現在、デュアルオレキシン受容体拮抗薬（DORA）が注目されていますが、選択的オレキシン受容体1（OX1R）またはオレキシン受容体2（OX2R）拮抗薬の開発も続けられています。この動きは、治療効果に磨きをかけ、おそらく、より少ない標的外副作用で睡眠覚醒サイクルをよりコントロールできるようにしようとするものです。
• 実際のエビデンスの重視市場に出回るオレキシン拮抗薬の数が増えるにつれ、対照臨床試験を超えて、様々な患者集団における有効性と安全性を証明する実臨床エビデンスの収集にスポットライトが当たるようになってきました。この動きは、処方行動や市場参入への情報提供に役立ち、長期的な患者の転帰に関する知識を広げます。
• デジタルヘルスソリューションとの統合：市場の動向として、睡眠モニタリングアプリや不眠症の認知行動療法（CBT-I）プログラムなどのデジタルヘルスソリューションにオレキシン拮抗薬治療を統合するという新しい動きがあります。ホリスティックな実践は、治療コンプライアンスを向上させ、睡眠パターンを追跡し、患者を徹底的にサポートするように設計されています。

これらの動向は、オレキシン拮抗薬の市場を、より高度で統合された睡眠ウェルネスのコンセプトへと形成しています。慢性疾患への注目、より広い適応、個別化医療、デジタル化が革新を生み出し、睡眠疾患の治療範囲を拡大しています。

オレキシン拮抗薬市場の最近の動向

オレキシン拮抗薬市場は、睡眠の神経生物学の改善と不眠症に対するより良い治療法の必要性に後押しされ、継続的な発展を目の当たりにしています。最近の主な動向は、治療の幅を広げ、患者の利益を高め、これらの新薬へのアクセスを広げることに重点が置かれていることが特徴です。

• 新製品の承認と発売最も注目すべき進展は、主要市場における新しいデュアルオレキシン受容体拮抗薬（DORA）の承認と上市であり、特にダリドレキサント（Quviviq）がその代表です。これにより、患者や処方者にとって治療の選択肢が広がり、このクラスにおける競合と革新が高まりました。
• 日中機能改善の強調：新しいオレキシン拮抗薬の最新の臨床試験や発売マーケティングでは、単に夜間の睡眠だけでなく、日中の機能改善に焦点を当てるようになってきています。これは、不眠症が患者の日常機能に及ぼすより広範な影響を認識し、全体的に良好な効果を誘導する治療パラダイムの転換です。
• 長期安全性と有効性データ：承認されたオレキシン拮抗薬について、より包括的な長期安全性・有効性データが製薬会社から発表されています。このことは、処方者や患者の信頼性を高め、慢性的な使用を容易にし、一般に依存性や離脱症候群を伴う旧来の催眠薬との差別化に役立っています。
• 他の適応症に対するパイプライン開発：オレキシン拮抗薬の不眠症以外の治療可能性を明らかにするための研究が進行中です。この開発は、不安障害、うつ病、薬物使用障害などを対象とした臨床試験が進行中であることが特徴であり、市場の戦略的多様化とこれらの化合物のより大きな治療可能性を反映しています。
• 地理的拡大と市場へのアクセス：オレキシン拮抗薬は、欧州やアジアの主要市場など、さらに多くの国で販売承認を取得し、市販されるようになってきています。このような拡大は、これらの新しい治療法に対する患者のアクセスを増加させ、市場を世界的にさらに拡大させます。

このような進歩により、オレキシン拮抗薬市場は、睡眠障害の治療環境として、より広範で世界的に利用可能なものとなりつつあります。新製品の発売、日中の治療成績の向上、長期的なエビデンス、より幅広い適応により、オレキシン拮抗薬は現代の睡眠医学の基礎となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界のオレキシン拮抗薬市場：種類別

• 概要
• 魅力分析：種類別
• 選択的オレキシン受容体拮抗薬：動向と予測（2019～2031年）
• デュアルオレキシン受容体拮抗薬：動向と予測（2019～2031年）

第5章 世界のオレキシン拮抗薬市場：用途別

• 概要
• 魅力分析：種類別
• 病院・クリニック：動向と予測（2019～2031年）
• 小売薬局：動向と予測（2019～2031年）
• その他：動向と予測（2019～2031年）

第6章 地域分析

• 概要
• 世界のオレキシン拮抗薬市場：地域別

第7章 北米のオレキシン拮抗薬市場

• 概要
• 北米のオレキシン拮抗薬市場：種類別
• 北米のオレキシン拮抗薬市場：用途別
• 米国のオレキシン拮抗薬市場
• メキシコのオレキシン拮抗薬市場
• カナダのオレキシン拮抗薬市場

第8章 欧州のオレキシン拮抗薬市場

• 概要
• 北米のオレキシン拮抗薬市場：種類別
• 北米のオレキシン拮抗薬市場：用途別
• ドイツのオレキシン拮抗薬市場
• フランスのオレキシン拮抗薬市場
• スペインのオレキシン拮抗薬市場
• イタリアのオレキシン拮抗薬市場
• 英国のオレキシン拮抗薬市場

第9章 アジア太平洋のオレキシン拮抗薬市場

• 概要
• アジア太平洋のオレキシン拮抗薬市場：種類別
• アジア太平洋のオレキシン拮抗薬市場：用途別
• 日本のオレキシン拮抗薬市場
• インドのオレキシン拮抗薬市場
• 中国のオレキシン拮抗薬市場
• 韓国のオレキシン拮抗薬市場
• インドネシアのオレキシン拮抗薬市場

第10章 その他の地域 (ROW) のオレキシン拮抗薬市場

• 概要
• その他の地域 (ROW) のオレキシン拮抗薬市場：種類別
• その他の地域 (ROW) のオレキシン拮抗薬市場：用途別
• 中東のオレキシン拮抗薬市場
• 南米のオレキシン拮抗薬市場
• アフリカのオレキシン拮抗薬市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • 成長機会：種類別
  • 成長機会：用途別
• 世界のオレキシン拮抗薬市場の新たな動向
• 戦略分析
  • 新製品開発
  • 認証・ライセンシング
  • 企業合併・買収 (M&A) 、契約、提携、合弁事業

第13章 バリューチェーン上の主要企業のプロファイル

• 競合分析
• Merck
• Eisai
• Idorsia
• Sun Pharmaceutical

第14章 付録

• 図の一覧
• 表の一覧
• 分析手法
• 免責事項
• 著作権
• 略語と技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Orexin Antagonist Market
• Figure 2.1: Usage of Orexin Antagonist Market
• Figure 2.2: Classification of the Global Orexin Antagonist Market
• Figure 2.3: Supply Chain of the Global Orexin Antagonist Market
• Figure 2.4: Driver and Challenges of the Orexin Antagonist Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Orexin Antagonist Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Orexin Antagonist Market ($B) by Type
• Figure 4.3: Forecast for the Global Orexin Antagonist Market ($B) by Type
• Figure 4.4: Trends and Forecast for Selective Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2019-2031)
• Figure 4.5: Trends and Forecast for Dual Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2019-2031)
• Figure 5.1: Global Orexin Antagonist Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Orexin Antagonist Market ($B) by Application
• Figure 5.3: Forecast for the Global Orexin Antagonist Market ($B) by Application
• Figure 5.4: Trends and Forecast for Hospital & Clinic in the Global Orexin Antagonist Market (2019-2031)
• Figure 5.5: Trends and Forecast for Retail Pharmacies in the Global Orexin Antagonist Market (2019-2031)
• Figure 5.6: Trends and Forecast for Others in the Global Orexin Antagonist Market (2019-2031)
• Figure 6.1: Trends of the Global Orexin Antagonist Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Orexin Antagonist Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Orexin Antagonist Market (2019-2031)
• Figure 7.2: North American Orexin Antagonist Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Orexin Antagonist Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Orexin Antagonist Market ($B) by Type (2025-2031)
• Figure 7.5: North American Orexin Antagonist Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Orexin Antagonist Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Orexin Antagonist Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Orexin Antagonist Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Orexin Antagonist Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Orexin Antagonist Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Orexin Antagonist Market (2019-2031)
• Figure 8.2: European Orexin Antagonist Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Orexin Antagonist Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Orexin Antagonist Market ($B) by Type (2025-2031)
• Figure 8.5: European Orexin Antagonist Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Orexin Antagonist Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Orexin Antagonist Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Orexin Antagonist Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Orexin Antagonist Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Orexin Antagonist Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Orexin Antagonist Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Orexin Antagonist Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Orexin Antagonist Market (2019-2031)
• Figure 9.2: APAC Orexin Antagonist Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Orexin Antagonist Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Orexin Antagonist Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Orexin Antagonist Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Orexin Antagonist Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Orexin Antagonist Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Orexin Antagonist Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Orexin Antagonist Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Orexin Antagonist Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Orexin Antagonist Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Orexin Antagonist Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Orexin Antagonist Market (2019-2031)
• Figure 10.2: ROW Orexin Antagonist Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Orexin Antagonist Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Orexin Antagonist Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Orexin Antagonist Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Orexin Antagonist Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Orexin Antagonist Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Orexin Antagonist Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Orexin Antagonist Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Orexin Antagonist Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Orexin Antagonist Market
• Figure 11.2: Market Share (%) of Top Players in the Global Orexin Antagonist Market (2024)
• Figure 12.1: Growth Opportunities for the Global Orexin Antagonist Market by Type
• Figure 12.2: Growth Opportunities for the Global Orexin Antagonist Market by Application
• Figure 12.3: Growth Opportunities for the Global Orexin Antagonist Market by Region
• Figure 12.4: Emerging Trends in the Global Orexin Antagonist Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Orexin Antagonist Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Orexin Antagonist Market by Region
• Table 1.3: Global Orexin Antagonist Market Parameters and Attributes
• Table 3.1: Trends of the Global Orexin Antagonist Market (2019-2024)
• Table 3.2: Forecast for the Global Orexin Antagonist Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Orexin Antagonist Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Orexin Antagonist Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Orexin Antagonist Market (2025-2031)
• Table 4.4: Trends of Selective Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2019-2024)
• Table 4.5: Forecast for Selective Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2025-2031)
• Table 4.6: Trends of Dual Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2019-2024)
• Table 4.7: Forecast for Dual Orexin Receptor Antagonist in the Global Orexin Antagonist Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Orexin Antagonist Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Orexin Antagonist Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Orexin Antagonist Market (2025-2031)
• Table 5.4: Trends of Hospital & Clinic in the Global Orexin Antagonist Market (2019-2024)
• Table 5.5: Forecast for Hospital & Clinic in the Global Orexin Antagonist Market (2025-2031)
• Table 5.6: Trends of Retail Pharmacies in the Global Orexin Antagonist Market (2019-2024)
• Table 5.7: Forecast for Retail Pharmacies in the Global Orexin Antagonist Market (2025-2031)
• Table 5.8: Trends of Others in the Global Orexin Antagonist Market (2019-2024)
• Table 5.9: Forecast for Others in the Global Orexin Antagonist Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Orexin Antagonist Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Orexin Antagonist Market (2025-2031)
• Table 7.1: Trends of the North American Orexin Antagonist Market (2019-2024)
• Table 7.2: Forecast for the North American Orexin Antagonist Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Orexin Antagonist Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Orexin Antagonist Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Orexin Antagonist Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Orexin Antagonist Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Orexin Antagonist Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Orexin Antagonist Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Orexin Antagonist Market (2019-2031)
• Table 8.1: Trends of the European Orexin Antagonist Market (2019-2024)
• Table 8.2: Forecast for the European Orexin Antagonist Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Orexin Antagonist Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Orexin Antagonist Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Orexin Antagonist Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Orexin Antagonist Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Orexin Antagonist Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Orexin Antagonist Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Orexin Antagonist Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Orexin Antagonist Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Orexin Antagonist Market (2019-2031)
• Table 9.1: Trends of the APAC Orexin Antagonist Market (2019-2024)
• Table 9.2: Forecast for the APAC Orexin Antagonist Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Orexin Antagonist Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Orexin Antagonist Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Orexin Antagonist Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Orexin Antagonist Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Orexin Antagonist Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Orexin Antagonist Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Orexin Antagonist Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Orexin Antagonist Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Orexin Antagonist Market (2019-2031)
• Table 10.1: Trends of the ROW Orexin Antagonist Market (2019-2024)
• Table 10.2: Forecast for the ROW Orexin Antagonist Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Orexin Antagonist Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Orexin Antagonist Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Orexin Antagonist Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Orexin Antagonist Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Orexin Antagonist Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Orexin Antagonist Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Orexin Antagonist Market (2019-2031)
• Table 11.1: Product Mapping of Orexin Antagonist Suppliers Based on Segments
• Table 11.2: Operational Integration of Orexin Antagonist Manufacturers
• Table 11.3: Rankings of Suppliers Based on Orexin Antagonist Revenue
• Table 12.1: New Product Launches by Major Orexin Antagonist Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Orexin Antagonist Market

The future of the global orexin antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global orexin antagonist market is expected to grow with a CAGR of 7.2% from 2025 to 2031. The major drivers for this market are the increasing prevalence of sleep disorders, the rising demand for effective insomnia treatment, and the growing awareness about orexin antagonists.

• Lucintel forecasts that, within the type category, dual orexin receptor antagonists are expected to witness higher growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Orexin Antagonist Market

The market for orexin antagonists is being addressed by some major trends that are being fueled by an enhanced knowledge of sleep physiology, changing patient requirements, and innovative drug development. These trends are impacting product development, clinical approaches, and the overall approach to the treatment of sleep disorders, changing towards more specific and patient-oriented therapies.

• Targeting Chronic Insomnia Disorder: There is a definite trend toward placing orexin antagonists as treatments for chronic insomnia disorder, highlighting their potential to treat the underlying mechanism of hyperarousal instead of simply sedating. This emphasis distinguishes them from older hypnotics, with the prospect of more natural sleep and better daytime functioning for long-term management.
• Exploration of Non-Insomnia Indications: In addition to insomnia, researchers are actively exploring orexin antagonists for other illnesses in which the orexin system is implicated, including anxiety, depression, and drug abuse. This development signals the promise for market expansion into other psychiatric and neurological disorders, opening up new therapeutic possibilities.
• Development of Selective Orexin Antagonists: Although dual orexin receptor antagonists (DORAs) are the current focus, efforts continue to develop selective orexin receptor 1 (OX1R) or orexin receptor 2 (OX2R) antagonists. This movement seeks to refine the therapeutic effects, perhaps providing more control over sleep-wake cycles with fewer off-target side effects.
• Real-World Evidence Emphasis: With increasing numbers of orexin antagonists making their way to the market, the spotlight has shifted towards gathering real-world evidence that proves their efficacy and safety in various patient populations beyond controlled clinical trials. This movement assists in informing prescribing behavior, market access, and broadens the knowledge of long-term patient outcomes.
• Integration with Digital Health Solutions: The trend in the market is a new trend of integrating orexin antagonist therapies into digital health solutions, including sleep monitoring apps and cognitive behavioral therapy for insomnia (CBT-I) programs. The holistic practice is designed to improve treatment compliance, track sleep patterns, and give thorough support to patients.

All these trends are together shaping the market for orexin antagonists into a more advanced and integrated concept of sleep wellness. Chronic illness focus, broader indications, individualized medicine, and digitization are creating innovation and expanding the therapeutic scope for sleep diseases.

Recent Developments in the Orexin Antagonist Market

The market for orexin antagonists is witnessing ongoing developments propelled by the improving neurobiology of sleep and the need for better treatments for insomnia. Recent major developments have been characterized by an emphasis on broadening the therapeutic armory, enhancing patient benefits, and widening access to these novel drugs.

• New Product Approvals and Launches: The most noteworthy evolution is the approval and launch of new dual orexin receptor antagonists (DORAs) in core markets, most notably daridorexant (Quviviq). This broadens the therapeutic choices for patients and prescribers, heightening competition and innovation in the class.
• Daytime Functioning Improvement Emphasis: The latest clinical trials and launch marketing for newer orexin antagonists increasingly focus on daytime functioning improvements, not merely nighttime sleep. This is a shift in treatment paradigm acknowledging the wider implications of insomnia for the daily functioning of patients and inducing overall good effects.
• Long-Term Safety and Efficacy Data: More comprehensive long-term safety and efficacy data are being published by pharmaceutical companies for approved orexin antagonists. This helps reinforce prescribers' and patients' confidence and facilitates chronic use, distinguishing the drugs from the older hypnotics that are generally linked with dependency or withdrawal syndrome.
• Pipeline Development for Other Indications: Studies are ongoing to reveal the therapeutic potential of orexin antagonists beyond insomnia. This development is characterized by ongoing clinical trials for conditions such as anxiety, depression, and substance use disorders, reflecting a strategic diversification of the market and greater therapeutic potential for these compounds.
• Geographic Expansion and Access to Markets: Orexin antagonists are increasingly receiving marketing approvals and becoming commercially available in additional countries, such as major markets in Europe and Asia. This expansion increases patient access to these new therapies and further expands the market globally.

These advancements are propelling the orexin antagonist market into a more extensive and world-available treatment environment for sleep disorders. New product launches, better daytime outcomes, long-term evidence, and broader indications are making orexin antagonists a foundation of contemporary sleep medicine.

Strategic Growth Opportunities in the Orexin Antagonist Market

The market for orexin antagonists offers substantial strategic growth potential through targeting specific patient segments and broadening therapeutic uses beyond primary insomnia. Strategically addressing these areas through development and marketing can open up new revenue opportunities and meet unmet medical needs.

• Chronic Insomnia Treatment: The most significant growth opportunity is to establish orexin antagonists as the first-line treatment of choice for chronic insomnia disorder. This includes widespread education of physicians and patients regarding their new mechanism of action, safe safety profile, and value for long-term sleep and daytime functioning.
• Insomnia with Comorbid Conditions: There is a significant opportunity in addressing insomnia that occurs with other medical or psychiatric illnesses, including depression, anxiety, or chronic pain. Orexin antagonists, with their potential to enhance sleep without sedative effects, present a compelling solution for these complicated patients.
• Sleep Maintenance Insomnia: Targeting specifically sleep maintenance insomnia (trouble staying asleep) reveals an important growth opportunity. Orexin antagonists, by suppressing wake drive during the night, are uniquely capable of enhancing sleep continuity, with an advantage over certain older hypnotics that act mainly on sleep onset.
• Substance Use Disorder and Sleep: Orexin antagonists have potential to treat sleep disturbances related to substance use disorders, possibly diminishing cravings and enhancing recovery rates. This is a strategic area of expansion that is meeting a major unmet need in the treatment of addiction, drawing on the orexin system's involvement in reward pathways.
• Geriatric Sleep Management: As the world's population ages, there's an increasing requirement for safe and effective sleep aids in the elderly, who are usually sensitive to the side effects of conventional hypnotics. Orexin antagonists, with their non-sedating action, present a good profile in this vulnerable population, representing a strategic growth opportunity.

These growth opportunities, which are key strategic drivers of the orexin antagonist market, are influencing the market by necessitating a more tailored and sophisticated approach to sleep disorder treatment. By targeting specialized patient populations and moving into comorbid conditions, the market is facing extensive growth and therapeutic diversification.

Orexin Antagonist Market Driver and Challenges

The orexin antagonist market is influenced by a sophisticated interplay of factors. These are the rising prevalence of sleep disorders, advances in neuroscience, and changing regulatory environments. Grasping these dynamics is important for everyone concerned, as they determine market growth, innovation, and patient access.

The factors responsible for driving the orexin antagonist market include:

1. Increasing Prevalence of Insomnia: The increasing prevalence of chronic insomnia globally, frequently attributed to contemporary lifestyles, stress, and aging populations, is a major driver. The widespread nature of this condition presents a large patient population in search of effective and acceptable sleep remedies.

2. Improved Safety Profile over Conventional Hypnotics: Orexin antagonists provide a differentiated safety profile with reduced risk of dependence, abuse, and next-day residual effects over benzodiazepines and Z-drugs. Improved safety motivates physician preference and patient compliance, driving market uptake.

3. Novel Mechanism of Action: The unique mechanism of action of orexin antagonists, selectively inhibiting wakefulness as opposed to sedating the brain broadly, is a strong motivator. Clinicians wanting more physiological sleep induction and patients who want rest to feel natural both find the targeted approach appealing.

4. Rising Awareness and Diagnosis of Sleep Disorders: Increased public and medical awareness of the health implications of chronic insomnia is resulting in higher diagnosis rates. This enhanced identification of the condition directly results in increased demand for effective prescribed medications such as orexin antagonists.

5. Positive Clinical Outcomes and Evidence: Strong clinical trial evidence of olanzapine-associated significant improvements in sleep onset, maintenance, and daytime functioning for approved orexin antagonists lends confidence. Such a sound therapeutic basis supports their global therapeutic implementation and reinforces the value of their therapy.

Challenges in the orexin antagonist market are:

1. High Price and Reimbursement Barriers: Orexin antagonists are newcomers and tend to be more expensive than generic established hypnotics, creating an access and reimbursement challenge. Payers often impose prior authorization or fail-first requirements, limiting utilization in cost-conscious healthcare systems.

2. Physician and Patient Education Requirements: Being a newer drug class, there is a high requirement for continued education for healthcare professionals and patients on the distinct mechanism of action, advantages, and correct usage of orexin antagonists. Overcoming resistance to change with previous prescribing patterns is a challenge.

3. Competition with Established and Generic Sleep Aids: The insomnia treatment market is saturated with long-standing and generic benzodiazepines, Z-drugs, and even over-the-counter products. Orexin antagonists have to constantly prove their higher value proposition to compete favorably with these easily accessible and frequently lower-cost products.

The market for orexin antagonists is heavily influenced by the increasing disease burden of insomnia, the positive safety profile of drugs, and their novel mechanism of action. High prices, requirement of intensive education, and competition with existing treatments are major challenges, and the market needs strategic pricing, transparent communication, and ongoing evidence generation to ensure long-term penetration.

List of Orexin Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, orexin antagonist companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the orexin antagonist companies profiled in this report include:

• Merck
• Eisai
• Idorsia
• Sun Pharmaceutical

Orexin Antagonist Market by Segment

The study includes a forecast for the global orexin antagonist market by type, application, and region.

Orexin Antagonist Market by Type [Value from 2019 to 2031]:

• Selective Orexin Receptor Antagonist
• Dual Orexin Receptor Antagonist

Orexin Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Orexin Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Orexin Antagonist Market

The orexin antagonist market, a new generation of drugs chiefly for insomnia, is growing fast with its novel mechanism of action focused on wakefulness. Recent trends involve new drug approvals, widened geographic reach, and continued research into other therapeutic uses aside from sleep disorders, revolutionizing the way sleep and wakefulness are treated.

• United States: The US market has witnessed considerable adoption of approved dual orexin receptor antagonists such as suvorexant, lemborexant, and daridorexant. Developments center on augmenting physician and patient education, investigating real-world effectiveness, and navigating the arrival of generics as patents approach expiration, affecting market dynamics.
• China: China is a developing market with increasing awareness of insomnia as a public health issue. Recent advances include the approval of investigational new drug (IND) filings for DORAs, including daridorexant, via licensing arrangements with foreign firms. This reflects a move toward the introduction of new sleep therapies to the large Chinese population.
• Germany: Germany recently experienced the introduction and growing availability of dual orexin receptor antagonists such as daridorexant. Here, developments highlight the drug's unique mechanism of action, presenting an alternative method of treating insomnia to that of conventional hypnotics through enhanced sleep quality and functioning during the day.
• India: The Indian market for orexin antagonists is still in its infancy, with increased awareness of insomnia as a major health condition. Work is mainly centered on the investigation and evaluation of known orexin receptor antagonists, pending a possible future market entry when pharmaceutical firms evaluate the space for these new sleep therapies.
• Japan: Japan has actively embraced orexin antagonists, with the launch of lemborexant by Eisai and daridorexant by Nxera Pharma and Shionogi. Recent developments highlight the country's proactive approach to adopting new insomnia treatments, with a focus on improving sleep quality and addressing specific patient needs.

Features of the Global Orexin Antagonist Market

• Market Size Estimates: Orexin antagonist market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Orexin antagonist market size by type, application, and region in terms of value ($B).
• Regional Analysis: Orexin antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the orexin antagonist market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the orexin antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the orexin antagonist market by type (selective orexin receptor antagonist and dual orexin receptor antagonist), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Orexin Antagonist Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Selective Orexin Receptor Antagonist: Trends and Forecast (2019-2031)
• 4.4 Dual Orexin Receptor Antagonist: Trends and Forecast (2019-2031)

5. Global Orexin Antagonist Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital & Clinic: Trends and Forecast (2019-2031)
• 5.4 Retail Pharmacies: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Orexin Antagonist Market by Region

7. North American Orexin Antagonist Market

• 7.1 Overview
• 7.2 North American Orexin Antagonist Market by Type
• 7.3 North American Orexin Antagonist Market by Application
• 7.4 United States Orexin Antagonist Market
• 7.5 Mexican Orexin Antagonist Market
• 7.6 Canadian Orexin Antagonist Market

8. European Orexin Antagonist Market

• 8.1 Overview
• 8.2 European Orexin Antagonist Market by Type
• 8.3 European Orexin Antagonist Market by Application
• 8.4 German Orexin Antagonist Market
• 8.5 French Orexin Antagonist Market
• 8.6 Spanish Orexin Antagonist Market
• 8.7 Italian Orexin Antagonist Market
• 8.8 United Kingdom Orexin Antagonist Market

9. APAC Orexin Antagonist Market

• 9.1 Overview
• 9.2 APAC Orexin Antagonist Market by Type
• 9.3 APAC Orexin Antagonist Market by Application
• 9.4 Japanese Orexin Antagonist Market
• 9.5 Indian Orexin Antagonist Market
• 9.6 Chinese Orexin Antagonist Market
• 9.7 South Korean Orexin Antagonist Market
• 9.8 Indonesian Orexin Antagonist Market

10. ROW Orexin Antagonist Market

• 10.1 Overview
• 10.2 ROW Orexin Antagonist Market by Type
• 10.3 ROW Orexin Antagonist Market by Application
• 10.4 Middle Eastern Orexin Antagonist Market
• 10.5 South American Orexin Antagonist Market
• 10.6 African Orexin Antagonist Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Orexin Antagonist Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Merck
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Eisai
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Idorsia
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sun Pharmaceutical
  • Company Overview
  • Orexin Antagonist Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us